Trial Profile
Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms BocepreVIH
- 05 May 2016 Results of a pharmacogenetic substudy (n=232) from ANRS HC26 and HC27 studies published in the AIDS.
- 01 Mar 2016 Results published in the HIV Clinical Trials.
- 12 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.